GlaxoSmithKline and Valeant Pharmaceuticals International Receive EU Marketing Authorization for Seizure Drug

WP -- GlaxoSmithKline PLC says its seizure drug developed with Valeant Pharmaceuticals Inc. has been granted marketing authorization by the European Union. Trobalt is intended to treat partial onset seizures in adults with epilepsy. The EU approval comes after the Committee for Medicinal Products for Human Use recommended Trobalt be approved for patients who are already using another therapy. The committee makes recommendations to the European Medicines Agency.